Eupraxia Pharmaceuticals Inc. (EPRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 40-F for FY2025, filed Mar 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EPRX SEC filings page.
Eupraxia Pharmaceuticals Inc. (EPRX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Eupraxia Pharmaceuticals Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Eupraxia Pharmaceuticals Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Eupraxia Pharmaceuticals Inc. reported a net loss of $38.6M while operations used $28.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Eupraxia Pharmaceuticals Inc. held $80.6M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
EPRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
EPRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2540-F | Q4'2440-F | Q4'2310-K | Q4'2210-K |
|---|---|---|---|---|
| Total Assets | $86.2M+146.5% | $34.9M+72.4% | $20.3M+6.0% | $19.1M |
| Current Assets | $85.1M+147.1% | $34.4M+73.9% | $19.8M+6.5% | $18.6M |
| Cash & Equivalents | $80.6M+143.4% | $33.1M+71.1% | $19.3M+5.9% | $18.3M |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Accounts Receivable | $716K+177.5% | $258K+67.9% | $154K | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.7M+83.8% | $3.1M-84.0% | $19.4M+62.6% | $11.9M |
| Current Liabilities | $5.6M+81.4% | $3.1M-84.0% | $19.4M+533.5% | $3.1M |
| Non-Current Liabilities | $76K | $0 | $0-100.0% | $8.9M |
| Total Equity | $82.0M+145.6% | $33.4M+1407.3% | $2.2M-71.5% | $7.8M |
| Retained Earnings | -$169.6M-29.4% | -$131.0M-24.2% | -$105.5M-36.5% | -$77.3M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
EPRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
EPRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. EPRX | FY2025 | $0 | -$38.6M | N/A | $441.4M | — |
| Entrada Therapeutics, Inc. TRDA | FY2025 | $25.4M | -$143.8M | N/A | $214.2M | 41/100 |
| Tiziana Life Sciences Ltd. TLSA | FY2025 | N/A | -$18.4M | N/A | $138.7M | — |
| Heron Therapeutics, Inc. HRTX | FY2025 | $154.9M | -$20.0M | -12.9% | $78.9M | 46/100 |
| Elicio Therapeutics, Inc. ELTX | FY2025 | N/A | -$39.6M | N/A | $49.4M | — |
| SELLAS Life Sciences Group, Inc. SLS | FY2025 | N/A | -$26.9M | N/A | $2.4B | — |
Where Eupraxia Pharmaceuticals Inc. Ranks
Frequently Asked Questions
What is Eupraxia Pharmaceuticals Inc.'s annual revenue?
Eupraxia Pharmaceuticals Inc. (EPRX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Eupraxia Pharmaceuticals Inc. profitable?
No, Eupraxia Pharmaceuticals Inc. (EPRX) reported a net income of -$38.6M in fiscal year 2025.
What is Eupraxia Pharmaceuticals Inc.'s return on equity (ROE)?
Eupraxia Pharmaceuticals Inc. (EPRX) has a return on equity of -47.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Eupraxia Pharmaceuticals Inc.'s operating cash flow?
Eupraxia Pharmaceuticals Inc. (EPRX) recorded an outflow of $28.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Eupraxia Pharmaceuticals Inc.'s total assets?
Eupraxia Pharmaceuticals Inc. (EPRX) had $86.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Eupraxia Pharmaceuticals Inc. spend on research and development?
Eupraxia Pharmaceuticals Inc. (EPRX) invested $21.3M in research and development during fiscal year 2025.
What is Eupraxia Pharmaceuticals Inc.'s current ratio?
Eupraxia Pharmaceuticals Inc. (EPRX) had a current ratio of 15.12 as of fiscal year 2025, which is generally considered healthy.
What is Eupraxia Pharmaceuticals Inc.'s debt-to-equity ratio?
Eupraxia Pharmaceuticals Inc. (EPRX) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Eupraxia Pharmaceuticals Inc.'s return on assets (ROA)?
Eupraxia Pharmaceuticals Inc. (EPRX) had a return on assets of -44.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Eupraxia Pharmaceuticals Inc.'s P/E ratio?
Eupraxia Pharmaceuticals Inc. (EPRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $441.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Eupraxia Pharmaceuticals Inc.'s price-to-sales ratio?
Eupraxia Pharmaceuticals Inc. (EPRX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $441.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Eupraxia Pharmaceuticals Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Eupraxia Pharmaceuticals Inc. (EPRX) held $80.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $28.6M over that year. Dividing the one by the other, the reported balance equals about 34 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Eupraxia Pharmaceuticals Inc.'s Piotroski F-Score?
Eupraxia Pharmaceuticals Inc. (EPRX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Eupraxia Pharmaceuticals Inc.'s earnings high quality?
Eupraxia Pharmaceuticals Inc. (EPRX) reported a net loss of $38.6M while operations used $28.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.